-
-
-
-
-
-
-
Fusion Pharmaceuticals (FUSN) is 'sole remaining clinical-stage, targeted radiopharm player,' seen as takeover target - Oppenheimer
-
-
-
-
-
-
-
Alexandria Real Estate Equities, Inc. Announces Exclusive Partnership With Lilly to Expand Lilly Gateway Labs to San Diego
-
-
-
-
-
-
-
POINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
-
-
-
-
-
-
-
Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities into Next-Generation Radioligand Therapies
-
-
-
-
-
-
-
Lilly Reports Second-Quarter 2023 Financial Results, Highlights Accelerating Revenue Growth and Key Pipeline Advancements
-
-
-
-
-
-
-
Eli Lilly & Co. (LLY) to Acquire Sigilon Therapeutics (SGTX) for $14.92/sh plus CVR
-
-
-
-
-
-
-
Lilly to Divest BAQSIMI to Amphastar
-
923,449 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All